As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don't take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Over the past year, we have concentrated our efforts and resources on advocating for regulatory and legislative reforms and commonsense policies to lower domestic drug prices and expand access to lower cost medication from pharmacies in other countries. (more…)
Last week, Gabriel Levitt, founder of Prescription Justice, published an Op-Ed in The Guardian about Alex Azar, President Trump's nominee for Secretary of the Department of Health and Human Services (HHS). Mr. Levitt's Op-Ed, Alex Azar is big pharma personified. He must not become US health secretary, underscores the urgent need for members of Congress to oppose Azar's confirmation.
During recent testimony before the Senate Health, Education, Labor and Pension Committee hearing on Stabilizing the Affordable Care Act Marketplace, AARP became the largest consumer organization to publicly support the prescription drug policy solutions reflected in Prescription Justice’s policy platform. AARP supports commonsense policy reforms to allow Medicare to negotiate drug prices, end pay-for-delay deals that delay entry of generic drugs into the marketplace, and increase access to lower cost medications through safe prescription drug importation. As part of a larger set of priorities for protecting and strengthening the healthcare system, AARP boldly declared that any changes to the healthcare law must include solutions to address rising prescription drug costs. (more…)
Recently, The Hill featured the Op-Ed, A tale of two drug bills — one proposed bill will worsen the drug prices crisis, by Gabriel Levitt, President of Prescription Justice. Mr. Levitt’s Op-Ed provides an insightful look at legislation targeting two distinct public health problems, but only one has the capacity to inflict further devastation from the public health crisis that is high drug prices.
The Synthetics Trafficking & Overdose Prevention Act of 2017 (STOP Act), introduced by Sen. Rob Portman (R- OH) aims to stop the flow of the highly addictive synthetic opioid fentanyl from coming into the U.S. by requiring the U.S. Postal Service (USPS) to obtain information about packages coming from foreign sources. Unlike private carriers such as UPS and FedEx, the USPS does not currently require advanced electronic customs data from much of the mail received at its International Mail centers.
The Brussels Principles underscore the importance of the international online marketplace as a lifeline of affordable medication for the millions of people forced to go without necessary treatment due to drug cost and availability.
On March 31st, 2017, Prescription Justice organized a panel for the RightsCon 2017 conference in Brussels, which addressed protecting online access to safe and affordable medication. The organizers of RightsCon just published their outcomes document in which Prescription Justice’s effort to bring together both medicines access and Internet freedom advocates was recognized.
At that conference, the participants discussed a set of draft principles pertaining to medication sales over the Internet and prescription drug importation. The prevailing position among the panelists was that initiatives funded by the pharmaceutical industry that affect access to medicines on the Internet were detrimental to the cause of prescription drug affordability.